Clinical Trials Browser

Not yet recruiting × Specimen Handling × Gastrointestinal × Clear all

NCT07619521 2026-06-02

Testing the Combination of Anti-Cancer Drugs, Selumetinib and DS-8201a, for Advanced Pancreatic Ductal Adenocarcinoma

Phase 1/2 Not yet recruiting

Gastrointestinal

Pancreatic Neoplasms

NCT07612007 2026-06-01

HRX215, A First Generation MKK4 Inhibitor Drug, for the Treatment of Patients With Colorectal Liver Metastasis After Undergoing a Portal Vein Embolization

Phase 2 Not yet recruiting

Gastrointestinal

Colorectal Neoplasms

NCT07595874 2026-05-27

NEST3

Phase 2 Not yet recruiting

Gastrointestinal

Colonic Neoplasms, Rectal Neoplasms

NCT07608627 2026-05-27

64Cu-DOTA A2 scFv-Fc2 DM With Positron Emission Tomography for the Imaging of Patients With Locally Advanced or Metastatic PSCA-Expressing Pancreatic Cancer

Phase 1 Not yet recruiting

Gastrointestinal

Pancreatic Neoplasms

NCT07594626 2026-05-19

BMS-986504 in Combination With Pemetrexed for the Treatment of Metastatic Solid Tumors With MTAP Deletion

Phase 1/2 Not yet recruiting

Gastrointestinal

Colonic Neoplasms, Esophageal Neoplasms, Gastrointestinal Neoplasms, Neoplasm Metastasis, Pancreatic Neoplasms

NCT07594548 2026-05-18

Futibatinib With Paclitaxel and Ramucirumab for the Treatment of Locally Advanced or Unresectable Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma

Phase 1 Not yet recruiting

Gastrointestinal

Adenocarcinoma Of Esophagus

NCT07551596 2026-05-15

Testing the Combination of Anti-Cancer Drugs, Botensilimab (AGEN1181) and Balstilimab (AGEN2034), After Standard Treatment for Colorectal Cancer, Combat Trial

Phase 2 Not yet recruiting

Gastrointestinal

Colorectal Neoplasms

NCT06732388 2026-05-13

Itraconazole in Combination With Ablation for the Prevention of Esophageal Cancer in Patients With High-risk Barrett's Esophagus

Phase 2 Not yet recruiting

Gastrointestinal

Adenocarcinoma Of Esophagus, Barrett Esophagus

NCT07439484 2026-05-11

PRECISE

Phase NA Not yet recruiting

Gastrointestinal

Clinical Stage I Esophageal Adenocarcinoma American Joint Committee on Cancer (AJCC) v8

NCT07576725 2026-05-08

Low Dose, Reduced Frequency Nivolumab for the Treatment of Unresectable or Metastatic Cancer, AFFORD IO Trial

Phase 2 Not yet recruiting

DermatologicGastrointestinalGenitourinaryGynecologicHead & NeckLymphoidSarcomaThoracic

Clear-cell metastatic renal cell carcinoma, Squamous Cell Carcinoma of Head and Neck, Carcinoma, Basal Cell, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Carcinoma, Transitional Cell, Uterine Cervical Neoplasms, Hodgkin Disease, Lung Neoplasms, Melanoma, Neoplasm Metastasis, Sarcoma, Kaposi, Colorectal Neoplasms, Carcinoma, Merkel Cell

NCT07511504 2026-04-06

Y-90 Radioembolization, Durvalumab, Tremelimumab, and Zanzalintinib for the Treatment of Unresectable and Locally-Advanced Hepatocellular Carcinoma

Phase 2 Not yet recruiting

Gastrointestinal

Carcinoma, Hepatocellular

NCT07363408 2026-01-23

Ivonescimab and ADG126, Alone, and in Combination With Leucovorin and Fluorouracil or FOLFIRI Regimen for the Treatment of Microsatellite Stable Advanced/Metastatic Colorectal Cancer

Phase 1 Not yet recruiting

Gastrointestinal

Colorectal Neoplasms

NCT07271355 2025-12-09

Pressurized Intraperitoneal Aerosolized Chemotherapy With Mitomycin for the Treatment of Unresectable Appendix or Colorectal Cancer With Peritoneal Metastases, The IMPACT Trial

Phase 3 Not yet recruiting

Gastrointestinal

Appendiceal Neoplasms, Colorectal Neoplasms

NCT07042919 2025-06-29

Zanzalintinib in Second Line and Beyond for the Treatment of Advanced Liver Cancer

Phase 1/2 Not yet recruiting

Gastrointestinal

Fibrosis, Carcinoma, Hepatocellular